Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment

被引：44

作者：

Sasada, Tetsuro ^{[1
]}

Azuma, Koichi ^{[2
]}

Ohtake, Junya ^{[1
]}

Fujimoto, Yuki ^{[1
]}

机构：

[1] Kanagawa Canc Ctr Res Inst, Canc Vaccine Ctr, Yokohama, Kanagawa, Japan

[2] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka 830, Japan

来源：

FRONTIERS IN PHARMACOLOGY | 2016年 / 7卷

关键词：

EGFR; mutation; cellular immune response; humoral immune response; PD-L1; CELL LUNG-CANCER; PERSONALIZED PEPTIDE VACCINE; PD-L1; EXPRESSION; UP-REGULATION; T-CELLS; AUTOANTIBODIES; ACTIVATION; SURVIVAL; PATHWAY; ESCAPE;

D O I：

10.3389/fphar.2016.00405

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Epidermal growth factor receptor (EGFR) is a prototypic cell-surface receptor belonging to the ErbB/HER onocogene family. Overexpression or somatic mutations of EGFR have been reported to play an important role in tumorigenesis in various types of epithelial cancers. Therefore, targeting of EGFR with specific blocking antibodies or inhibitors have been developing for treatment for EGFR-associated tumors. Immune responses to HER2, another molecule of the ErbB/HER onocogene family, have been well studied, but only limited information on the immune responses to EGFR in cancer has been currently available. In this review, we have summarized the available data and discussed potential clinical importance of the anti-EGFR immune responses and EGFR-mediated immune regulation in cancer. Several lines of evidence suggest that cellular and humoral immune responses to EGFR might be useful as a marker and/or target for cancer therapy against EGFR-associated tumors. In addition, recent studies suggest the critical roles of EGFR-mediated signaling in regulation of expression of an immune checkpoint molecule, programmed death-ligand 1 (PD-L1) in tumor cells. Further studies are warranted to clarify the impact of the anti-EGFR immune responses and EGFR-mediated immunomodulation for clinical application for cancer treatment.

引用

页数：7

共 46 条

[1] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[2] Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients [J].

Andrade Filho, Pedro A. ;

Lopez-Albaitero, Andres ;

Gooding, William ;

Ferris, Robert L. .

JOURNAL OF IMMUNOTHERAPY, 2010, 33 (01) :83-91

[3]

[Anonymous], 2014, NANOMEDICINE, DOI DOI 10.1186/2045-3701-4-67

[4] Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer [J].

Azuma, K. ;

Ota, K. ;

Kawahara, A. ;

Hattori, S. ;

Iwama, E. ;

Harada, T. ;

Matsumoto, K. ;

Takayama, K. ;

Takamori, S. ;

Kage, M. ;

Hoshino, T. ;

Nakanishi, Y. ;

Okamoto, I. .

ANNALS OF ONCOLOGY, 2014, 25 (10) :1935-1940

[5] Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib [J].

Azuma, Koichi ;

Komatsu, Nobukazu ;

Hattori, Satoshi ;

Matsueda, Satoko ;

Kawahara, Akihiko ;

Sasada, Tetsuro ;

Itoh, Kyogo ;

Hoshino, Tomoaki .

PLOS ONE, 2014, 9 (01)

[6] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].

Baselga, J ;

Arteaga, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459

[7] Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity [J].

Caruso, Hillary G. ;

Hurton, Lenka V. ;

Najjar, Amer ;

Rushworth, David ;

Ang, Sonny ;

Olivares, Simon ;

Mi, Tiejuan ;

Switzer, Kirsten ;

Singh, Harjeet ;

Huls, Helen ;

Lee, Dean A. ;

Heimberger, Amy B. ;

Champlin, Richard E. ;

Cooper, Laurence J. N. .

CANCER RESEARCH, 2015, 75 (17) :3505-3518

[8] Autoantibodies in lung cancer:: possibilities for early detection and subsequent cure [J].

Chapman, C. J. ;

Murray, A. ;

McElveen, J. E. ;

Sahin, U. ;

Luxemburger, U. ;

Tuereci, Oe ;

Wiewrodt, R. ;

Barnes, A. C. ;

Robertson, J. F. .

THORAX, 2008, 63 (03) :228-233

[9] Super-resolved enhancing and edge deghosting (SEED) for spatiotemporally encoded single-shot MRI [J].

Chen, Lin ;

Li, Jing ;

Zhang, Miao ;

Cai, Shuhui ;

Zhang, Ting ;

Cai, Congbo ;

Chen, Zhong .

MEDICAL IMAGE ANALYSIS, 2015, 23 (01) :1-14

[10] Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [J].

Chen, Nan ;

Fang, Wenfeng ;

Zhan, Jianhua ;

Hong, Shaodong ;

Tang, Yanna ;

Kang, Shiyang ;

Zhang, Yaxiong ;

He, Xiaobo ;

Zhou, Ting ;

Qin, Tao ;

Huang, Yan ;

Yi, Xianping ;

Zhang, Li .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) :910-923

← 1 2 3 4 5 →